R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ  OLABİLİR Mİ?

Kayacan Yıldırım; Yazar Hayrullah; Özdin Mehmet

doi:https://dx.doi.org/10.26650/IUITFD.2021.824074

Araştırma Makalesi

DOI :10.26650/IUITFD.2021.824074 IUP :10.26650/IUITFD.2021.824074 Tam Metin (PDF)

R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?

Yıldırım Kayacan, Hayrullah Yazar, Mehmet Özdin

Amaç: Çalışmanın amacı, COVID-19 hastalarında R oranının bir gösterge olup olamayacağını belirlemektir. Gereç ve Yöntem: Tüm hastaların (n=314) ilk kan serumunda alkalin fosfataz (ALP) ve alanin aminotransferaz (ALT) ölçülerek R değerleri belirlendi ve gruplandı. Daha sonra tespit edilen parametreler arasındaki korelasyonlar incelenerek ve farklılıklar cinsiyete göre analiz edildi. Ayrıca hastalar referans aralığın ALT ve ALP üst değerlerine göre karşılaştırıldı. Alfa değeri <0,05 olarak kabul edildi. Bulgular: Tüm hastalarda, ALT ve ALP normal referans aralıklarının oldukça üzerinde tespit edildi (p=0,000). R-değeri oranı, ALT ve ALP ile önemli ölçüde ilişkiliydi (p<0,001). R grupları istatistiksel olarak anlamlı ve yaşla ters orantılıydı (p=0,049). Kadınlarda ≥5 R oranının erkeklere göre daha yüksek olduğu tespit edildi. Sonuç: Bulgularımıza göre COVID-19 tanısı alan hastalarda ölçülen ALT ve ALP normalden çok daha yüksekti. Araştırmamızın bir başka ilginç sonucu da hastalarımızın çoğunda R-oranının ≤2 olarak bulunmasıydı. Akut karaciğer hasarının bir göstergesi olarak kabul edilen R≤2 bulgusu, COVID-19 için bu değerin izlenmesinin önemli bir gösterge olabileceğini düşündürmektedir

Anahtar Kelimeler: SARS-CoV-2, COVID-19, R-Oranı, ALT, ALP

DOI :10.26650/IUITFD.2021.824074 IUP :10.26650/IUITFD.2021.824074 Tam Metin (PDF)

COULD THE R-RATIO BE AN INDICATOR OF ACUTE LIVER INJURY FOR THE TREATMENT OF COVID-19?

Yıldırım Kayacan, Hayrullah Yazar, Mehmet Özdin

Objective: The aim of the study was to determine whether the R-ratio could be an indicator in COVID-19 patients. Material and Method: Alkaline phosphatase (ALP) and alanine aminotransferase (ALT) were measured in the first blood serum of all patients (n=314), and R-values were determined and grouped. Then, the correlations between the detected parameters were examined and the differences were analyzed by gender. Patients were compared according to the ALT and ALP upper values of the reference interval. Alpha value was accepted as <0.05. Results: In all patients, ALT and ALP were detected well above normal reference ranges (p=0.000). The R-value ratio was significantly associated with ALT and ALP (p<0.001). R-groups were statistically significant and inversely proportional to age (p=0.049). It was detected that the R-ratio of ≥5 was higher in women than in men. Conclusion: According to our findings, ALT and ALP measurements in patients diagnosed with COVID-19 were much higher than normal. Another interesting result of our research was that the R-ratio was found to be ≤2 in the majority of our patients. The R≤2 finding, which is accepted as an indicator of acute liver injury, suggested that tracking of this value for COVID-19 could be an important indicator.

Anahtar Kelimeler: SARS-CoV-2, COVID-19, R-Ratio, ALT, ALP

Referanslar

1. Wang Y, Chen J, Chen Y, Wu XT. Improvement of nonalcoholic fatty liver disease in ALT at >/=12 months after Roux-en-Y gastric bypass and sleeve gastrectomy, no effect in ALT and AST at <12 months after SG and in AST at >12 and </=24 months after RYGB. Surg Obes Relat Dis 2020;16(3):447-50. [CrossRef] google scholar
2. Moss DW, Henderson RA. Clinical Enzymology In: Burtis CA, Ashwood ER, eds Tietz textbook of clinical chemistry Philadelphia: WB Saunders Company, 1999; 676-84. google scholar
3. Friedman L. S, Chopra S, Travis A. C. Approach to the patient with abnormal liver biochemical and function tests. Up to Date, 2014. google scholar
4. Yao WH, Wei XL, Guo H, Cheng D, Li H, Sun LM, et al. Tributyltin reduces bone mineral density by reprograming bone marrow mesenchymal stem cells in rat. Environ Toxicol Phar 2020;73:103271. [CrossRef] google scholar
5. Thomas L. Alkaline phosphatase (ALP) In: Thomas L, ed Clinical laboratory diagnostics Use and assessment of clinical laboratory results Frankfurt/Main: TH-Books Verlagsgesellschaft, 1998:36-46. google scholar
6. Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, et al. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area. Zhonghua Gan Zang Bing Za Zhi 2020;28(3):229-33. google scholar
7. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020:5(5):428-30. [CrossRef] google scholar
8. Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY) 2020;12(12):11245-58. [CrossRef] google scholar
9. Zimmerman HJ, Ishak KG. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 1995;24(4):739-57. [CrossRef] google scholar
10. Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol. 2008;24(3):287-97. [CrossRef] google scholar
11. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006:44(6):1581-88. [CrossRef] google scholar
12. Wroblewski F, Ladue JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med 1956:91(4):569-71. [CrossRef] google scholar
13. Bergmeyer HU, Horder M. International federation of clinical chemistry. Scientific committee. Expert panel on enzymes. IFCC document stage 2, draft 1; 1979-11-19 with a view to an IFCC recommendation. IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase. J Clin Chem Clin Biochem 1980:18(8):521-34. google scholar
14. Bowers GN, Jr., McComb RB. Measurement of total alkaline phosphatase activity in human serum. Clin Chem 1975:21(13):1988-95. [CrossRef] google scholar
15. Tietz NW. Textbook of Clinical Chemistry, W.B. Saunders, (ed). 1986. google scholar
16. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur Respir J 2020;55(5):2000524. [CrossRef] google scholar
17. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 2020;81(1):30208-5. [CrossRef] google scholar
18. Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int 2020;14(5):690-700. [CrossRef] google scholar
19. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;73(3):566-74. [CrossRef] google scholar
20. Zhao X-Y, Xu X-X, Yin H-S, Hu Q-M, Xiong T, Tang Y-Y, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis 2020;20:311. [CrossRef] google scholar
21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. [CrossRef] google scholar
22. Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep 2020;2(3):100113. [CrossRef] google scholar
23. Barrasa H, Rello J, Tejada S, Martın A, Balziskueta G, Vinuesa C, et al. COVID19 Study Investigators SARS-Cov-2 in Spanish Intensive Care: Early Experience with 15-day Survival in Vitoria. Anaesth Crit Care Pain Med 2020;39(5):553-61. [CrossRef] google scholar
24. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Characteristics of Liver Tests in COVID-19 Patients. J Hepatol 2020;73(3):566-74. [CrossRef] google scholar
25. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354(7):731-39. [CrossRef] google scholar
26. Watkins PB. Idiosyncratic drug-induced liver injury in patients: Detection, severity assessment and, regulatory implications. Adv Pharmacol 2019;85:165-93. [CrossRef] google scholar
27. Whritenour J, Ko M, Zong Q, Wang J, Tartaro K, Schneider P, et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol 2017;14(1):31-8 [CrossRef] google scholar
28. Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology 2020;159(2):768-71. [CrossRef] google scholar
29. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy 2021;76(2):428-55. [CrossRef] google scholar
30. Ali N. Relationship Between COVID-19 Infection and Liver Injury: A Review of Recent Data. Front Med-Lausanne 2020, 7. [CrossRef] google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın

DIŞA AKTAR

APA

Kayacan, Y., Yazar, H., & Özdin, M. (2021). R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?. İstanbul Tıp Fakültesi Dergisi, 84(3), 311-317. https://doi.org/10.26650/IUITFD.2021.824074

AMA

Kayacan Y, Yazar H, Özdin M. R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?. İstanbul Tıp Fakültesi Dergisi. 2021;84(3):311-317. https://doi.org/10.26650/IUITFD.2021.824074

ABNT

Kayacan, Y.; Yazar, H.; Özdin, M. R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?. İstanbul Tıp Fakültesi Dergisi, [Publisher Location], v. 84, n. 3, p. 311-317, 2021.

Chicago: Author-Date Style

Kayacan, Yıldırım, and Hayrullah Yazar and Mehmet Özdin. 2021. “R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?.” İstanbul Tıp Fakültesi Dergisi 84, no. 3: 311-317. https://doi.org/10.26650/IUITFD.2021.824074

Chicago: Humanities Style

Kayacan, Yıldırım, and Hayrullah Yazar and Mehmet Özdin. “R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?.” İstanbul Tıp Fakültesi Dergisi 84, no. 3 (Nov. 2024): 311-317. https://doi.org/10.26650/IUITFD.2021.824074

Harvard: Australian Style

Kayacan, Y & Yazar, H & Özdin, M 2021, 'R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?', İstanbul Tıp Fakültesi Dergisi, vol. 84, no. 3, pp. 311-317, viewed 23 Nov. 2024, https://doi.org/10.26650/IUITFD.2021.824074

Harvard: Author-Date Style

Kayacan, Y. and Yazar, H. and Özdin, M. (2021) ‘R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?’, İstanbul Tıp Fakültesi Dergisi, 84(3), pp. 311-317. https://doi.org/10.26650/IUITFD.2021.824074 (23 Nov. 2024).

MLA

Kayacan, Yıldırım, and Hayrullah Yazar and Mehmet Özdin. “R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?.” İstanbul Tıp Fakültesi Dergisi, vol. 84, no. 3, 2021, pp. 311-317. [Database Container], https://doi.org/10.26650/IUITFD.2021.824074

Vancouver

Kayacan Y, Yazar H, Özdin M. R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?. İstanbul Tıp Fakültesi Dergisi [Internet]. 23 Nov. 2024 [cited 23 Nov. 2024];84(3):311-317. Available from: https://doi.org/10.26650/IUITFD.2021.824074 doi: 10.26650/IUITFD.2021.824074

ISNAD

Kayacan, Yıldırım - Yazar, Hayrullah - Özdin, Mehmet. “R ORANI, COVID-19 TEDAVİSİNDE AKUT KARACİĞER HASARININ BİR GÖSTERGESİ OLABİLİR Mİ?”. İstanbul Tıp Fakültesi Dergisi 84/3 (Nov. 2024): 311-317. https://doi.org/10.26650/IUITFD.2021.824074

Cilt 84, Sayı 32021, S. 311-317

ZAMAN ÇİZELGESİ

Gönderim	10.11.2020
Kabul	17.02.2021
Çevrimiçi Yayınlanma	02.07.2021

LİSANS

Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.

İstanbul Tıp Fakültesi Dergisi